CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug ...
MADRID — A simple home-based screening strategy that involved wearing an ECG patch for 14 days increased the diagnosis of atrial fibrillation (AF) and associated use of anticoagulants in patients at ...
SAN DIEGO, July 09, 2025--(BUSINESS WIRE)--Vektor Medical, a medical technology company transforming standard ECG data into actionable insights that guide arrhythmia care, today announced that Baptist ...
A mail-based atrial fibrillation (AF) screening programme with ECG-patch monitoring led to a modest long-term increase in AF diagnosis and anticoagulation exposure in older patients at ...
MADRID, Spain—The use of a noninvasive ECG patch modestly increases the detection of atrial fibrillation (AF) and treatment with anticoagulant therapy among patients at moderate to high risk for ...
New decision establishes reimbursement for the clinical use of Tempus ECG-AF, reducing the financial burden of using AI to improve early detection of atrial fibrillation CHICAGO--(BUSINESS WIRE)-- ...
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ...
(RTTNews) - Tempus AI, Inc (TEM), Wednesday announced that the company has received 510(k) clearance from the U.S. Food and Drug Administration for its Tempus ECF-AF, which utilizes AI to detect ...
Atrial fibrillation (AF) is the most common arrhythmia and is a leading cause of stroke and heart failure yet often remains ...
Researchers conducted a subanalysis of the prospective Omron Heart study in Japan from April 2022 through July 2023, enrolling 3820 adults aged 60 years and above with hypertension. Participants used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results